Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Refludan
Drug ID BADD_D01920
Description Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.
Indications and Usage For the treatment of heparin-induced thrombocytopenia
Marketing Status Discontinued
ATC Code B01AE02
DrugBank ID DB00001
KEGG ID D06880
MeSH ID C083544
PubChem ID 118856773
TTD Drug ID D09LPN
NDC Product Code Not Available
Synonyms lepirudin | 1-Leu-2-Thr-63-desulfohirudin | HBW 023 | HBW-023 | Refludan | Refludin | Aventis Brand Lepirudin
Chemical Information
Molecular Formula C287H440N80O111S6
CAS Registry Number 138068-37-8
SMILES CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C( =O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC (=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3 CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(= O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C= C4)O)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C )C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC( CCCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CNC=N7)C(=O)NC(CC(=O)N )C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C( =O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O )NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCC N)CCC(=O)O)CC(=O)O)CO)CC(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemoptysis22.02.03.004; 02.01.02.006; 24.07.01.006--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Haemothorax24.07.01.008; 22.05.02.001; 12.01.03.002--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Hypovolaemia14.05.05.002--Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.005--
Liver function test abnormal13.03.01.013--Not Available
Menopausal symptoms21.02.02.002--Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.001--
Nausea07.01.07.001--
Oedema08.01.07.006; 14.05.06.010--Not Available
Pain08.01.08.004--
Pericardial effusion02.06.01.002--
Pericardial haemorrhage24.07.01.013; 02.06.01.003--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages